Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...

Fixed-duration obinutuzumab–venetoclax was most common (51.1%), BTK inhibitors 26.2%, and venetoclax–ibrutinib 16.0%, with no frontline chemotherapy used across participating French centers.

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue their conversation on communicating ...

An international study has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help doctors better match patients with the therapies ...

There are two types of inflammation: acute and chronic. Acute inflammation is the kind that lasts a few hours, days, or weeks, and it’s helpful to healing. It’s your immune system’s response when ...

Recovering from chronic stress is possible. Lifestyle modifications, relaxation routines, and reframing unhelpful thoughts are all strategies that may help reduce the long-term effects of stress.